Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2016: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
|
Outline of Final Research Achievements |
Cancer stem cells are resistant to conventional chemotherapies and responsible for cancer initiation, invasive growth, and metastasis formation. The aim of this study is to develop a novel therapeutic strategy targeting biliary tract and pancreatic cancer stem cells. The newly developed 3D culture system called “organoid culture” allows long-term expansion of LGR5 positive stem cells into budding cyst-like structures (organoids) with properties resembling those of the original tissues. To reach our goal, we established organoids derived from biliary tract cancers and pancreatic cancers. We analyzed gene mutation and gene expression and performed drug screening test using these cancer organoids. Here we demonstrated that low molecular compounds and tumor suppressor microRNAs including miR-34a are safe and effective therapeutic drug candidates against biliary tract and pancreatic cancers.
|